Skip to main content
. 2011 Jan;178(1):261–272. doi: 10.1016/j.ajpath.2010.11.020

Figure 2.

Figure 2

Analysis of FKRP mRNA knockdown in GAS muscles after intramuscular injection of AAV6 shFKRP vectors. At the 2-month time point, quantitative RT-PCR analyses of FKRP mRNA in the muscle samples showed significant knockdown in groups treated with shFKRP5 (48.3 ± 10.1%) and shFKRP2 + 5 (71.6 ± 1.2%) but not in the group treated with shFKRP2 (10.6 ± 10.8%). However, at the 10-month time point, FKRP mRNA was knocked down in all AAV-treated groups, shFKRP2 (46.4 ± 4.1%), shFKRP5 (45.0 ± 7.4%), and dual shFKRP2 + 5 (72.3% ± 7.8%) (n = 5, mean ± SD; * P < 0.05).